Bibliographic Details
| Title: |
Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma |
| Authors: |
Sabrina Manni, Anna Fregnani, Laura Quotti Tubi, Zaira Spinello, Marco Carraro, Greta Scapinello, Andrea Visentin, Gregorio Barilà, Marco Pizzi, Angelo Paolo Dei Tos, Fabrizio Vianello, Renato Zambello, Carmela Gurrieri, Gianpietro Semenzato, Livio Trentin, Francesco Piazza |
| Source: |
Frontiers in Oncology, Vol 11 (2021) |
| Publisher Information: |
Frontiers Media S.A., 2021. |
| Publication Year: |
2021 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
mantle cell lymphoma, CK1α, BCR inhibitors, ibrutinib, duvelisib, targeted therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
Mantle Cell Lymphoma (MCL) is still an incurable B-cell malignancy characterized by poor prognosis and frequent relapses. B Cell Receptor (BCR) signaling inhibitors, in particular of the kinases BTK and PI3Kγ/δ, have demonstrated clinically meaningful anti-proliferative effects in B cell tumors. However, refractoriness to these drugs may develop, portending a dismal prognosis. Protein kinase CK1α is an emerging pro-growth enzyme in B cell malignancies. In multiple myeloma, this kinase sustains β-catenin and AKT-dependent survival and is involved in the activation of NF-κB in B cells. In this study, we analyzed the role of CK1α on MCL cell survival and proliferation, on the regulation of BCR-related BTK, NF-κB, PI3K/AKT signaling cascades and the effects of CK1α chemical inhibition or gene silencing in association with the BTK inhibitor Ibrutinib or the PI3Kγ/δ inhibitor Duvelisib. CK1α was found highly expressed in MCL cells as compared to normal B cells. The inactivation/loss of CK1α caused MCL cell apoptosis and proliferation arrest. CK1α sustained BCR signaling, in particular the NF-κB, AKT and BTK pathways by modulating the phosphorylation of Ser 652 on CARD11, Ser 536 p65 on NF-κB, Ser 473 on AKT, Tyr 223 on BTK, as well as the protein levels. We also provided evidence that CK1α-mediated regulation of CARD11 and BTK likely implicates a physical interaction. The combination of CK1α inhibition with Ibrutinib or Duvelisib synergistically increased cytotoxicity, leading to a further decrease of the activation of BCR signaling pathways. Therefore, CK1α sustains MCL growth through the regulation of BCR-linked survival signaling cascades and protects from Ibrutinib/Duvelisib-induced apoptosis. Thus, CK1α could be considered as a rational molecular target for the treatment of MCL, in association with novel agents. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2234-943X |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fonc.2021.733848/full; https://doaj.org/toc/2234-943X |
| DOI: |
10.3389/fonc.2021.733848 |
| Access URL: |
https://doaj.org/article/c56d9b095bbc411ca2589e2e8f63ba58 |
| Accession Number: |
edsdoj.56d9b095bbc411ca2589e2e8f63ba58 |
| Database: |
Directory of Open Access Journals |
